Trexquant Investment LP Acquires 141,722 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Trexquant Investment LP increased its stake in Elanco Animal Health by 41.2%, now holding 485,605 shares valued at approximately $5.1 million.
• Institutional investors collectively own 97.48% of Elanco's shares, with notable increases from multiple firms in the first quarter.
• Elanco's recent earnings report showed a net margin of 9.68% and revenue of $1.24 billion, surpassing analysts' expectations.

Trexquant Investment LP increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 41.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 485,605 shares of the company's stock after purchasing an additional 141,722 shares during the quarter. Trexquant Investment LP owned approximately 0.10% of Elanco Animal Health worth $5,099,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP grew its stake in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after acquiring an additional 2,090 shares in the last quarter. CoreCap Advisors LLC purchased a new position in Elanco Animal Health during the 4th quarter valued at about $29,000. Parallel Advisors LLC grew its stake in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after acquiring an additional 1,852 shares in the last quarter. NBC Securities Inc. purchased a new position in Elanco Animal Health during the 1st quarter valued at about $40,000. Finally, Versant Capital Management Inc grew its stake in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after acquiring an additional 1,740 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

NYSE:ELAN traded up $0.93 during mid-day trading on Friday, hitting $18.40. 6,921,928 shares of the stock were exchanged, compared to its average volume of 10,348,335. The stock has a market capitalization of $9.14 billion, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62. The firm's 50-day simple moving average is $15.95 and its 200 day simple moving average is $12.93. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ELAN. UBS Group lifted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Piper Sandler lifted their target price on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, August 11th. Finally, Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and an average target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.